SG11201809512TA - Synapse formation agent - Google Patents

Synapse formation agent

Info

Publication number
SG11201809512TA
SG11201809512TA SG11201809512TA SG11201809512TA SG11201809512TA SG 11201809512T A SG11201809512T A SG 11201809512TA SG 11201809512T A SG11201809512T A SG 11201809512TA SG 11201809512T A SG11201809512T A SG 11201809512TA SG 11201809512T A SG11201809512T A SG 11201809512TA
Authority
SG
Singapore
Prior art keywords
synapse formation
promoter
formation agent
chronic
phase
Prior art date
Application number
SG11201809512TA
Inventor
Osamu Honmou
Masanori Sasaki
Rie Maezawa
Shinichi Oka
Yuko Sasaki
Masahito NAKAZAKI
Toshihiko Yamashita
Original Assignee
Univ Sapporo Medical
Nipro Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sapporo Medical, Nipro Corp filed Critical Univ Sapporo Medical
Publication of SG11201809512TA publication Critical patent/SG11201809512TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Medicinal Preparation (AREA)

Abstract

SYNAPSE FORMATION AGENT The present invention relates to a synapse formation promoter and a brain plasticity promoter comprising CD24- negative mesenchymal stem cells prepared from a patient's own bone marrow aspirate and treatment of dementia, chronic-phase cerebral infarction, chronic-phase spinal cord injury, mental diseases, and the like using the synapse formation promoter and brain plasticity promoter. [No Suitable Figure]
SG11201809512TA 2016-04-28 2017-04-26 Synapse formation agent SG11201809512TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016091286 2016-04-28
JP2016091300 2016-04-28
PCT/JP2017/017325 WO2017188457A1 (en) 2016-04-28 2017-04-26 Synapse formation agent

Publications (1)

Publication Number Publication Date
SG11201809512TA true SG11201809512TA (en) 2018-11-29

Family

ID=60160788

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809512TA SG11201809512TA (en) 2016-04-28 2017-04-26 Synapse formation agent

Country Status (10)

Country Link
US (2) US11666601B2 (en)
EP (1) EP3449930A4 (en)
JP (2) JP7101367B2 (en)
KR (2) KR20190004307A (en)
CN (1) CN109069542A (en)
AU (2) AU2017258058B2 (en)
CA (1) CA3022275A1 (en)
IL (2) IL299420A (en)
SG (1) SG11201809512TA (en)
WO (1) WO2017188457A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11666601B2 (en) * 2016-04-28 2023-06-06 Sapporo Medical University Synapse formation agent
WO2019077410A1 (en) * 2017-10-16 2019-04-25 Performance Phenomics Inc. Methods and apparatus for using brain imaging to predict performance
WO2020162580A1 (en) 2019-02-07 2020-08-13 北海道公立大学法人 札幌医科大学 Pharmaceutical composition for preventing in-stent restenosis
WO2020184729A1 (en) 2019-03-14 2020-09-17 北海道公立大学法人札幌医科大学 Pharmaceutical composition for treating amyotrophic lateral sclerosis
WO2021029346A1 (en) 2019-08-09 2021-02-18 国立大学法人東北大学 Agent for treating or preventing cerebrovascular dementia
JP2022027109A (en) 2020-07-31 2022-02-10 ニューロテックメディカル株式会社 Therapeutic agent for neuropathy
JP2022086174A (en) 2020-11-30 2022-06-09 ニューロテックメディカル株式会社 Therapeutic agents for neurological disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1302534A4 (en) 2000-06-26 2004-06-16 Renomedix Inst Inc Cell fraction containing cells capable of differentiating into neural cells
US20120269774A1 (en) * 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
WO2008066330A1 (en) * 2006-11-30 2008-06-05 Medipost Co., Ltd. Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells
KR102087366B1 (en) 2007-09-11 2020-03-10 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 Cell growth method and pharmaceutical preparation for tissue repair and regeneration
KR20100054711A (en) 2008-11-14 2010-05-25 메디포스트(주) Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases
EP2405912A2 (en) * 2009-03-12 2012-01-18 University Of South Florida Method of disease-induced and receptor-mediated stem cell neuroprotection
WO2012018040A1 (en) 2010-08-03 2012-02-09 北海道公立大学法人札幌医科大学 Autoserum-containing bone marrow cell culture system, autoserum-containing bone marrow cell culture method, and method for producing medicinal composition comprising autoserum-containing cultured bone marrow cells as active ingredient
JP5598864B2 (en) * 2011-12-05 2014-10-01 北海道公立大学法人 札幌医科大学 Cell proliferation method and medicament for tissue repair and regeneration
US11666601B2 (en) * 2016-04-28 2023-06-06 Sapporo Medical University Synapse formation agent

Also Published As

Publication number Publication date
AU2017258058B2 (en) 2023-04-13
AU2017258058A1 (en) 2018-11-15
KR20220166875A (en) 2022-12-19
IL262621B2 (en) 2023-05-01
JP7450896B2 (en) 2024-03-18
AU2023204405A1 (en) 2023-08-03
IL262621B1 (en) 2023-01-01
EP3449930A4 (en) 2019-11-20
US11666601B2 (en) 2023-06-06
WO2017188457A1 (en) 2017-11-02
JP7101367B2 (en) 2022-07-15
IL262621A (en) 2018-12-31
JP2022126812A (en) 2022-08-30
US20190117700A1 (en) 2019-04-25
CA3022275A1 (en) 2017-11-02
IL299420A (en) 2023-02-01
US20240122988A1 (en) 2024-04-18
CN109069542A (en) 2018-12-21
JPWO2017188457A1 (en) 2019-03-07
EP3449930A1 (en) 2019-03-06
KR20190004307A (en) 2019-01-11

Similar Documents

Publication Publication Date Title
SG11201809512TA (en) Synapse formation agent
MX2017005940A (en) Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders.
EP3934736A4 (en) Wearable peripheral nerve stimulation for the treatment of diseases utilizing rhythmic biological processes
EA201891224A1 (en) METHODS AND SYSTEMS FOR PROVIDING STIMULUS FOR THE BRAIN
TN2012000067A1 (en) Oxazine derivatives and their use in the treatment of neurological disorders
PT3377637T (en) Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
MX2018012207A (en) Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders.
MX2018012211A (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders.
MX2013006595A (en) Treatment of spinal cord injury and traumatic brain injury using placental stem cells.
EP3429605A4 (en) Therapeutic for treatment of diseases including the central nervous system
MX2018012208A (en) Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders.
WO2014106238A8 (en) Heterocyclic compounds and methods of use thereof
MX2021007592A (en) Macrocyclic compounds and their use in the treatment of disease.
MX2012010657A (en) Amino -dihydrooxazine and amino - dihydrothiazine spiro compounds as beta - secretase modulators and their medical use.
IL287032A (en) Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
IL288195A (en) Use of cannabidiol in the treatment of epileptic spasms
IL287280A (en) Compounds and methods for the treatment of ocular disorders
MX2018008644A (en) 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-deca ne derivatives.
PH12018500859A1 (en) Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease
CA2904533C (en) Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
MX2018008643A (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives.
GB2557471A (en) Arginine silicate inositol for improving cognitive function
MX2017015292A (en) Composition for treating brain lesions.
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders